Evolocumab intensive lipid-lowering therapy on prognosis of post-cerebral infarction depression

Table 6 Clinical events and safety outcomes during 24-week follow-up, n (%)

Event	Intensive group (n = 72)	Standard group (n = 72)	P value
Recurrent cerebrovascular events
Any event	3 (4.2)	9 (12.5)	0.065
Ischemic stroke	2 (2.8)	7 (9.7)	0.085
Transient ischemic attack	1 (1.4)	2 (2.8)	0.560
Hospitalization
All-cause rehospitalization	11 (15.3)	22 (30.6)	0.027
Cardiovascular rehospitalization	5 (6.9)	13 (18.1)	0.038
Depression-related hospitalization	3 (4.2)	11 (15.3)	0.021
Depression relapse
HAMD-17 ≥ 14 after response	8 (11.1)	21 (29.2)	0.007
Mean time to relapse (weeks), mean ± SD	18.3 ± 2.7	14.6 ± 3.1	0.003
Adverse events
Any adverse event	15 (20.8)	12 (16.7)	0.518
Injection site reaction	7 (9.7)	0 (0)	0.006
Myalgia (without CK elevation)	4 (5.6)	3 (4.2)	0.699
Elevated ALT (> 3 × ULN)	0 (0)	1 (1.4)	0.316
New-onset diabetes	2 (2.8)	4 (5.6)	0.403
Serious adverse events	1 (1.4)	2 (2.8)	0.560
All-cause death	0 (0)	1 (1.4)	0.316

Depression relapse defined as 17-item Hamilton Depression Rating Scale ≥ 14 after achieving treatment response. HAMD-17: 17-item Hamilton Depression Rating Scale; CK: Creatine kinase; ALT: Alanine aminotransferase; ULN: Upper limit of normal.